FDA Approves Drug To Treat Signs Of Equine Cushing’s Disease
November 2, 2011
Boehringer Ingelheim Vetmedica Inc. received approval from the Food and Drug Administration to market a drug for treatment of the clinical signs associated with pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s disease. Prascend, Boehringer’s registered trademark for the drug pergolide mesylate, is the first and only FDA-approved product for the management of… Continue reading...